Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada

Trial Profile

Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Haemophilus influenzae-pneumococcal vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Haemophilus infections; Otitis media; Pneumococcal infections; Pneumonia
  • Focus Therapeutic Use
  • Acronyms Nunavik2
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Sep 2016 to 31 Dec 2017.
    • 01 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 31 Dec 2017.
    • 19 Oct 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top